Quest Diagnostics Incorporated
DGX
$175.56
$3.892.27%
| Weiss Ratings | DGX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C | |||
| Reward Grade | B | |||
| Rating Factors | DGX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Fair | |||
| Growth Index | Fair | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | DGX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.27 | |||
| Price History | DGX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.21% | |||
| 30-Day Total Return | 15.61% | |||
| 60-Day Total Return | 12.12% | |||
| 90-Day Total Return | 11.67% | |||
| Year to Date Total Return | 16.87% | |||
| 1-Year Total Return | 40.73% | |||
| 2-Year Total Return | 32.95% | |||
| 3-Year Total Return | 37.20% | |||
| 5-Year Total Return | 76.94% | |||
| 52-Week High % Change | -3.60% | |||
| 52-Week Low % Change | 37.24% | |||
| Price | DGX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $178.09 | |||
| 52-Week Low Price | $125.09 | |||
| 52-Week Low Price (Date) | Mar 14, 2024 | |||
| 52-Week High Price (Date) | Mar 03, 2025 | |||
| Valuation | DGX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 19.05B | |||
| Enterprise Value | 25.74B | |||
| Price/Earnings (TTM) | 22.23 | |||
| Earnings Per Share (TTM) | 7.72 | |||
| Earnings Per Share Growth | 3.81% | |||
| Price/Earnings To Growth | 5.85 | |||
| Price/Sales (TTM) | 1.97 | |||
| Price/Book (Q) | 2.81 | |||
| Enterprise Value/Revenue (TTM) | 2.61 | |||
| Price | $175.56 | |||
| Enterprise Value/EBITDA (TTM) | 13.53 | |||
| Enterprise Value/EBIT | 18.26 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | DGX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 113.00M | |||
| Dividend Yield | 1.75% | |||
| Div. Per Share (Most Recent) | $0.75 | |||
| Dividend Per Share (TTM) | $3.00 | |||
| Payout Ratio (TTM) | 38.00% | |||
| Dividend Per Share (Most Recent) | $0.75 | |||
| Company Info | DGX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | (973) 520-2700 | |||
| Address | 500 Plaza Drive Secaucus, NJ 07094 | |||
| Website | www.questdiagnostics.com | |||
| Country | United States | |||
| Year Founded | 1967 | |||
| Profitability | DGX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 14.28% | |||
| Profit Margin | 8.82% | |||
| Management Effectiveness | DGX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 5.84% | |||
| Return on Equity | 13.84% | |||
| Income Statement | DGX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 9.87B | |||
| Total Revenue (TTM) | 9.87B | |||
| Revenue Per Share | $87.36 | |||
| Gross Profit (TTM) | 3.27B | |||
| EBITDA (TTM) | 1.90B | |||
| EBIT (TTM) | 1.41B | |||
| Net Income (TTM) | 871.00M | |||
| Net Income Avl. to Common (TTM) | 871.00M | |||
| Total Revenue Growth (Q YOY) | 14.55% | |||
| Earnings Growth (Q YOY) | 15.12% | |||
| EPS Diluted (TTM) | 7.72 | |||
| EPS Diluted Growth (Q YOY) | 20.21% | |||
| Balance Sheet | DGX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 549.00M | |||
| Cash Per Share (Q) | $4.86 | |||
| Total Current Assets (Q) | 2.39B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 6.90B | |||
| Current Ratio (Q) | 1.103 | |||
| Book Value Per Share (Q) | $61.06 | |||
| Total Assets (Q) | 16.15B | |||
| Total Current Liabilities (Q) | 2.17B | |||
| Total Debt (Q) | 7.12B | |||
| Total Liabilities (Q) | 9.26B | |||
| Total Common Equity (Q) | 6.78B | |||
| Cash Flow | DGX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -2.55B | |||
| Cash from Financing (TTM) | 1.08B | |||
| Net Change in Cash (TTM) | -137.00M | |||
| Levered Free Cash Flow (TTM) | 702.00M | |||
| Cash from Operations (TTM) | 1.33B | |||
